SINGAPORE, Jan. 15, 2016 /CNW/ -Zecotek Photonics Inc.
(TSX-V: ZMS; Frankfurt: W1I;
OTCPK: ZMSPF),), a developer of leading-edge photonics
technologies for industrial, healthcare and scientific markets, is
pleased to announce that the U.S. Patent office has issued a Notice
of Allowance for an enhanced LFS crystal array manufacturing
process which allows for more flexible production output at a
significantly improved price point. The enhanced process
produces LFS crystal arrays of various sizes and configurations at
a competitive price when compared to other crystal arrays and
single elements.
"This patent covers a break-through manufacturing process for a
key component of positron emission tomography and gamma scanning
devices," said Dr. A.F. Zerrouk,
Chairman, President, and CEO of Zecotek Photonics Inc. "Our
patented manufacturing process produces LFS crystal arrays of
variable size, quantity and configuration at a significant cost
advantage when compared to other crystal arrays and single
elements. Furthermore, with precise control on the pitch
dimension between individual elements, we are able to exactly match
crystal and detector arrays which significantly improves
performance of the array block. OEMs are continually searching
for better, more efficient ways to manufacture and produce their
imaging technologies and our scientific team keeps delivering
leading-edge components. This will provide extra consideration
choices for PET OEM's who are looking at using Zecotek's crystal in
their new PET machines. The unique crystal array configuration will
also give Zecotek the edge when assembled with its high performance
MAPD/MAPT photo-detector, a superior SiPM."
The LFS crystal block array is also a key component in Zecotek's
integrated detector module (IDM), a patent pending layered
structure made of an LFS crystal block array, an array of MAPD or
MAPT solid-state photo detectors, and a readout system.
The IDM is a cost effective and scalable design, ideal for new
positron emission tomography scanner configurations and various
types of gamma cameras. Escalating capital and maintenance
costs with current medical scanning devices are causing medical
organizations in the emerging economies of Brazil, Russia, India
and China, to redesign and build
their own. The IDM component represents approximately 70% of
the cost of a PET device, and combines key performance
characteristics of Zecotek's LFS scintillation crystals and MAPD or
MAPT solid-state photo detector and related technologies. It
has the opportunity to revolutionize the design and ongoing
maintenance of medical and scientific scanning devises
Zecotek's patented (US patent No. 7,132,060) LFS scintillation
crystals are known for their high light yields and ultra-fast decay
times which allow for faster and higher-resolution operation of
medical imaging equipment including PET medical scanners,
and industrial imaging devices used in high energy
physics experiments. Zecotek's LFS crystals also cover a
range of emission wavelengths which can match the spectral
sensitivity of various photo detectors including Zecotek`s
solid-state MAPD photo detector arrays.
LFS scintillation crystals are supplied by the Beijing
Opto-Electronics Technology Company (BOET), a subsidiary of
North-China Research Institute of Electronics-Optics an industry
leader in growing, cutting, polishing and large scale production
of scintillation crystals grown by the Czochralski
method. Zecotek's manufacturing process permits the
growth of very large-diameter boules with uniform properties and
without cracking (a problem with many competing scintillation
materials), resulting in high element output and lower unit
costs.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS;
Frankfurt: W1I) is a photonics technology company developing
high-performance scintillation crystals, photo detectors, positron
emission tomography scanning technologies, 3D auto-stereoscopic
displays, and lasers for applications in medical, high-tech and
industrial sectors. Founded in 2004, Zecotek operates three
divisions: Imaging Systems, Optronics Systems and 3D Display
Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on
building shareholder value by commercializing over 50 patented and
patent pending novel photonic technologies directly and through
strategic alliances and joint ventures with leading industry
partners including Hamamatsu Photonics (Japan), the European Organization for Nuclear
Research (Switzerland), Beijing
Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center
(South Korea). For more
information visit www.zecotek.com, and follow @zecotek on
Twitter.
This press release may contain forward-looking statements
that are based on management's expectations, estimates, projections
and assumptions. These statements are not guarantees of future
performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends
may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of the content of this news release. If you would like to
receive news from Zecotek in the future please visit the corporate
website at www.zecotek.com.
SOURCE Zecotek Photonics Inc.